- As China Slows Down, the Philippines Moves to Grab Foreign Investment
- Why Obamacare Subsidies Should Be Struck Down by the Supreme Court
- MannKind's Afrezza Earns Lackluster Review from Independent Drug Arbiter
- Shale Oil Bust Enters Phase Two, Led by Hercules and SandRidge
- Comcast Wants Congress to Gut the New Net Neutrality Rules
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
AbbVie announced it is buying cancer drug-maker Pharmacyclics for $21 billion.
The $21 billion price tag for Pharmacylics only earns AbbVie rights to 50% of the blood cancer drug Imbruvica.
The new Opdivo approval covers patients with squamous non-small cell lung cancer no longer responsive to chemotherapy, according to an announcement made the FDA.
The Securities and Exchange Commission's top cop wants drug companies to be more transparent with investors about their dealings with the U.S. Food and Drug Administration.
Obese Americans taking Contrave to lose weight cut their risk of having a heart attack, stroke or dying from heart disease by almost half compared to people taking a placebo.
The slow commercial launch of the inhaled insulin Afrezza coupled with growing downward pricing pressure for all diabetes products compels Goldman Sachs to slap a 'sell' rating on MannKind.
Chugai decision to license MultiStem for Japan will look prescient or foolish depending on the stem cell therapy's performance in an ongoing phase II study of stroke patients.
Afrezza is "modestly effective" at reducing blood glucose and its long-term safety is unknown, according to a review of the inhaled insulin published this week by The Medical Letter.
Amgen believes proving Kyprolis' superiority over Velcade in the second-line multiple myeloma treatment setting further justifies the $10.4 billion paid to Onyx Pharmaceuticals.